Recently, the stocks of Indian pharmaceutical manufacturers experienced a significant downturn. The catalyst for this decline was a statement by U.S. President Donald Trump, indicating that tariffs on pharmaceutical products are still under review. This announcement led to notable shifts in the stock market, particularly affecting the pharmaceutical sector in India.

The U.S. financial markets began the week with a sharp downturn in pharmaceutical and biotechnology stocks. On Monday, key industry players faced a decline in their stock prices following the news of Peter Marks' resignation as a leading figure in the Food and Drug Administration (FDA) responsible for vaccines. This unexpected departure marked the most significant personnel change in the regulator amidst a large-scale overhaul of federal health agencies spearheaded by Donald Trump's administration.